著者 頼 冠名| 瀧川 奈義夫| 伊藤 佐智夫| 柏原 宏美| 市原 英基| 保田 立二| 清水 憲二| 谷本 光音| 木浦 勝行|
発行日 2012-12-03
出版物タイトル 岡山医学会雑誌
124巻
3号
資料タイプ 学術雑誌論文
著者 Harada, Daijiro| Takigawa, Nagio| Ochi, Nobuaki| Ninomiya, Takashi| Yasugi, Masayuki| Kubo, Toshio| Takeda, Hiromasa| Ichihara, Eiki| Ohashi, Kadoaki| Takata, Saburo| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2012-10
出版物タイトル Cancer Science
103巻
10号
資料タイプ 学術雑誌論文
著者 Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro|
発行日 2012-07
出版物タイトル Lung Cancer
77巻
1号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/48564
フルテキストURL 66_3_245.pdf
著者 Okada, Toshiaki| Takigawa, Nagio| Kishino, Daizo| Katayama, Hideki| Kuyama, Shouichi| Sato, Ken| Mimoto, Junko| Ueoka, Hiroshi| Tanimoto, Mitsune| Kiura, Katsuyuki|
抄録 Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p<0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p<0.01, group 4 vs. group 6).
キーワード cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention
Amo Type Original Article
発行日 2012-06
出版物タイトル Acta Medica Okayama
66巻
3号
出版者 Okayama University Medical School
開始ページ 245
終了ページ 251
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22729105
Web of Science KeyUT 000305669700008
著者 Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro|
発行日 2012-04
出版物タイトル Lung Cancer
76巻
1号
資料タイプ 学術雑誌論文
著者 谷口 暁| 宮原 信明| 中原 淳| 高田 三郎| 佐久川 亮| 長野 修| 谷本 安| 金廣 有彦| 木浦 勝行| 氏家 良人| 谷本 光音|
発行日 2011-12-01
出版物タイトル 岡山医学会雑誌
123巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/47260
フルテキストURL 65_6_353.pdf
著者 Ichihara, Eiki| Kiura, Katsuyuki| Tanimoto, Mitsune|
抄録 Angiogenesis is an essential process in tumor growth. The concept of angiogenesis, when proposed by Folksman in 1971, had a great impact on cancer research and therapy, as the survival and proliferation of cancer depend on angiogenesis, which could be a target of cancer therapy. In subsequent decades, numerous antiangiogenic agents were developed, and some of them have been applied clinically. However, angiogenesis includes a complex and multistep process that has not been sufficiently elucidated. In this review, we focus on signaling pathways related with tumor angiogenesis and several antiangiogenic agents approved by the United States Food and Drug Administration or under investigation.
キーワード angiogenesis cancer
Amo Type Review
発行日 2011-12
出版物タイトル Acta Medica Okayama
65巻
6号
出版者 Okayama University Medical School
開始ページ 353
終了ページ 362
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22189475
Web of Science KeyUT 000298516900001
著者 Nogami, Naoyuki| Hotta, Katsuyuki| Kuyama, Shoichi| Kiura, Katsuyuki| Takigawa, Nagio| Chikamori, Kenichi| Shibayama, Takuo| Kishino, Daizo| Hosokawa, Shinobu| Tamaoki, Akihiko| Harita, Shingo| Tabata, Masahiro| Ueoka, Hiroshi| Shinkai, Tetsu| Tanimoto, Mitsune|
発行日 2011-10
出版物タイトル Lung Cancer
74巻
1号
資料タイプ 学術雑誌論文
著者 Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2011-09
出版物タイトル Molecular Cancer Therapeutics
10巻
9号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/46851
フルテキストURL 65_4_259.pdf
著者 Ogata, Yoshiko| Aoe, Keisuke| Hiraki, Akio| Murakami, Kazuo| Kishino, Daizo| Chikamori, Kenichi| Maeda, Tadashi| Ueoka, Hiroshi| Kiura, Katsuyuki| Tanimoto, Mitsune|
抄録 The objective of this study was to evaluate the utility of the determination of adenosine deaminase (ADA) level in pleural fluid for the differential diagnosis between tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) in Japan, a country with intermediate incidence of tuberculosis (TB). We retrospectively reviewed the clinical records of 435 patients with pleural effusion and investigated their pleural ADA levels as determined by an auto analyzer. ROC analysis was also performed. The study included patients with MPE (n=188), TPE (n=124), benign nontuberculous pleural effusion (n=94), and pleural effusion of unknown etiology (n=29). The median ADA level in the TPE group was 70.8U/L, which was significantly higher than that in any other groups (p<0.05). The area under the curve (AUC) in ROC analysis was 0.895. With a cut-off level for ADA of 36U/L, the sensitivity, specificity, positive predictive value, and negative predictive value were 85.5%, 86.5%, 69.7%, and 93.6%, respectively. As many as 9% of patients with lung cancer and 15% of those with mesothelioma were false-positive with this ADA cutoff setting. Although the ADA activity in pleural fluid can help in the diagnosis of TPE, it should be noted that some cases of lung cancer or mesothelioma show high ADA activity in geographical regions with intermediate incidence of TB, in contrast to high prevalence areas.
キーワード pleural effusion adenosine deaminase tuberculosis lung cancer mesothelioma
Amo Type Original Article
発行日 2011-08
出版物タイトル Acta Medica Okayama
65巻
4号
出版者 Okayama University Medical School
開始ページ 259
終了ページ 263
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 21860532
Web of Science KeyUT 000294236700006
著者 市原 英基| 大橋 圭明| 瀧川 奈義夫| 大澤 昌宏| 荻野 敦子| 谷本 光音| 木浦 勝行|
発行日 2011-04-01
出版物タイトル 岡山医学会雑誌
123巻
1号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/40503
フルテキストURL 64_5_285.pdf
著者 Nishimori, Hisakazu| Takahashi, Shunji| Kiura, Katsuyuki| Ennishi, Daisuke| Kobayashi, Takayuki| Sano, Koji| Shinozaki, Eiji| Yokoyama, Masahiro| Mishima, Yuko| Terui, Yasuhito| Chin, Keisho| Mizunuma, Nobuyuki| Ito, Yoshinori| Nishimura, Seiichiro| Takeuchi, Kengo| Ishikawa, Yuichi| Oguchi, Masahiko| Tanimoto, Mitsune| Hatake, Kiyohiko|
抄録 We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
キーワード cancer of unknown primary site (CUP) cisplatin docetaxel prognosis
Amo Type Original Article
発行日 2010-10
出版物タイトル Acta Medica Okayama
64巻
5号
出版者 Okayama University Medical School
開始ページ 285
終了ページ 291
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2010 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 20975761
Web of Science KeyUT 000283563300003
JaLCDOI 10.18926/AMO/32866
フルテキストURL fulltext.pdf
著者 Fujimoto, Nobukazu| Kiura, Katsuyuki| Takigawa, Nagio| Fujiwara, Yoshiro| Toyooka, Shinichi| Umemura, Shigeki| Tabata, Masahiro| Ueoka, Hiroshi| Tanimoto, Mitsune|
抄録 <p>We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were &#60;70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.</p>
キーワード cisplatin docetaxel irinotecan triplet chemotherapy gefitinib
Amo Type Original Article
発行日 2010-02
出版物タイトル Acta Medica Okayama
64巻
1号
出版者 Okayama University Medical School
開始ページ 33
終了ページ 37
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 20200582
Web of Science KeyUT 000274868300005
著者 市原 英基| 松岡 順治| 瀧川 奈義夫| 松崎 孝| 勝井 邦彰| 木浦 勝行| 谷本 光音|
発行日 2009-12-01
出版物タイトル 岡山医学会雑誌
121巻
3号
資料タイプ 学術雑誌論文
著者 末久 弘| 豊岡 伸一| 堀田 勝幸| 内田 亜希子| 宗 淳一| 藤原 義朗| 松尾 恵太郎| 大内田 守| 高田 穣| 木浦 勝行| 伊達 洋至|
発行日 2008-12-01
出版物タイトル 岡山医学会雑誌
120巻
3号
資料タイプ 学術雑誌論文
著者 木浦 勝行| 瀧川 奈義夫| 尾瀬 功| 八杉 昌幸| 越智 宣昭| 原田 大二郎| 谷本 光音|
発行日 2008-01-04
出版物タイトル 岡山医学会雑誌
119巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/30737
フルテキストURL fulltext.pdf
著者 Suzaki, Noriyuki| Hiraki, Akio| Takigawa, Nagio| Ueoka, Hiroshi| Tanimoto, Yasushi| Kozuki, Toshiyuki| Tabata, Masahiro| Kanehiro, Arihiko| Kiura, Katsuyuki| Tanimoto, Mitsune|
抄録 A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should be considered one of the possible life-threatening complications during treatment with paclitaxel.
キーワード paclitaxel adverse effect lung cancer interstitial pneumonia
Amo Type Article
発行日 2006-10
出版物タイトル Acta Medica Okayama
60巻
5号
出版者 Okayama University Medical School
開始ページ 295
終了ページ 298
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 17072376
Web of Science KeyUT 000241509000006
JaLCDOI 10.18926/AMO/30751
フルテキストURL fulltext.pdf
著者 Kitajima, Takuji| Nishii, Kenji| Ueoka, Hiroshi| Shibayama, Takuo| Gemba, Kenichi| Kodani, Tsuyoshi| Kiura, Katsuyuki| Tabata, Masahiro| Hotta, Katsuyuki| Tanimoto, Mitsune| Sobue, Tomotaka|
抄録 <p>To evaluate recent improvements in lung cancer screening, we compared the results of recently conducted lung cancer screening with those of a previous screening. This study compared the survival of lung cancer patients detected by lung cancer screening conducted between 1976 and 1984 (early period) with that conducted between 1989 and 1997 (late period). Two hundred seventy-six patients with lung cancer were detected in the early period and 541 patients with lung cancer were detected in the late period. The median survival time (late : 49.8 vs. early : 27.8 months) and the 5-year survival rate (late : 47.8 vs. early : 34.8%) of the patients with lung cancer detected in the late period were significantly better than those in the early period (p = 0.0054). Among patients undergoing resection, the proportion of pathological stage I patients in the late period was significantly higher than that in the early period (late : 60.8 vs. early : 54.9%, p = 0.005). Multivariate analysis showed that the screening time period was a significant prognostic factor (hazard ratio = 0.685, 95% confidence interval : 0.563-0.832, p = 0.0002). These results were consistent with the findings of case-control studies of lung cancer screening programs in the late period recently conducted in Japan, which also showed a greater efficacy for screening than for previous case-control studies in the early period.</p>
キーワード lung cancer screening survival lung cancer mortality
Amo Type Article
発行日 2006-06
出版物タイトル Acta Medica Okayama
60巻
3号
出版者 Okayama University Medical School
開始ページ 173
終了ページ 179
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16838046
Web of Science KeyUT 000238503600005
著者 木浦 勝行| 谷本 安| 田端 雅弘| 金廣 有彦| 上岡 博| 谷本 光音| 渡邊 都貴子| 草野 展周| 小出 典男|
発行日 2005-05-30
出版物タイトル 岡山医学会雑誌
115巻
1号
資料タイプ 学術雑誌論文
著者 谷本 安| 佐久川 亮| 木浦 勝行| 谷本 光音|
発行日 2005-01-31
出版物タイトル 岡山医学会雑誌
116巻
3号
資料タイプ 学術雑誌論文